Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ram K, Shrivastava"'
Autor:
Bijan Bastani, David V. Sheehan, Thomas Roth, Gregory M. Asnis, Ram K. Shrivastava, Maurizio Fava, Bruce Lydiard
Publikováno v:
Journal of Clinical Psychopharmacology. 29:222-230
A multicenter, double-blind, parallel-group study was designed to assess the efficacy and safety of zolpidem extended-release coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Patients (N = 383) rec
Autor:
Alan D. Feiger, Ward T. Smith, Jon F. Heiser, Ram K. Shrivastava, Michael Gibertini, J M A Sitsen, Kenneth J. Weiss
Publikováno v:
The Journal of Clinical Psychiatry. 64:243-249
OBJECTIVE To assess the efficacy and tolerability of the 5-HT(1A) agonist gepirone in extended-release formulation (gepirone-ER) versus placebo in patients with major depressive disorder. METHOD Patients aged 18 to 70 years were eligible if they sati
Autor:
Angela Williams, Raymond G. Hill, Guanghan Liu, Margaret A. Cascieri, John J. Sramek, John P. Feighner, Gary G. Chicchi, Ram K. Shrivastava, Malcolm MacCoss, Edward M. Scolnick, Duane B. Snavely, Emma J. Carlson, Louise Hewson, Christopher John Swain, Jeffrey J. Hale, Sharon Sadowski, N.R. Cutler, David D. Smith, Nadia M.J. Rupniak, Franz Hefti, Timothy Harrison, Edwina Wyatt-Knowles, Sander G. Mills, Scott A. Reines, Richard Hargreaves, John Carman, Mark S. Kramer
Publikováno v:
Science. 281:1640-1645
The localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that substance P antagonists might have psychotherapeutic properties. Like clinically used antidepressant and
Autor:
Ram K. Shrivastava, David V. Sheehan, Gregory M. Asnis, Maurizio Fava, Bruce Lydiard, Thomas Roth, Bijan Bastani
Publikováno v:
The Journal of clinical psychiatry. 72(7)
OBJECTIVE: This investigation was performed to assess the efficacy and safety of zolpidem extended-release in patients with insomnia associated with major depressive disorder (MDD). METHOD: Patients (N = 385) received open-label escitalopram 10 mg/d
Autor:
G.C. Dunbar, J.P. Feighner, L F Fabre, J. B. Cohn, R.R. Fieve, J. Mendels, Ram K. Shrivastava
Publikováno v:
British Journal of Psychiatry. 159:394-398
To compare the safety and antidepressant efficacy of paroxetine, imipramine, and placebo, data from six centres using the same protocol were pooled. A double-blind parallel-group design was used, with therapy lasting six weeks. From week 2 onwards, b
Autor:
Lynn A. Cunningham, Stuart Montgomery, George Tonelli, Ram K. Shrivastava, Lev Sverdlov, Joseph J. Hlavka, Ari Kiev, John P. Feighner
Publikováno v:
The international journal of neuropsychopharmacology. 9(5)
Nemifitide is a novel pentapeptide antidepressant, which appears to be effective in the treatment of major depressive disorder (MDD). In the present study 81 patients with MDD, DSM-IV criteria were randomized following a 1-wk screening period to rece
Autor:
Alan D, Feiger, Jon F, Heiser, Ram K, Shrivastava, Kenneth J, Weiss, Ward T, Smith, J M A, Sitsen, Michael, Gibertini
Publikováno v:
The Journal of clinical psychiatry. 64(3)
To assess the efficacy and tolerability of the 5-HT(1A) agonist gepirone in extended-release formulation (gepirone-ER) versus placebo in patients with major depressive disorder.Patients aged 18 to 70 years were eligible if they satisfied DSM-IV crite
Autor:
William M. Patterson, Chris Lines, James C. Ballenger, Scott A. Reines, Joseph Mendels, N.R. Cutler, Deborah Matzura-Wolfe, Alice Chenault, Ram K. Shrivastava, Mark S. Kramer
Publikováno v:
Biological psychiatry. 37(7)
The functional role of cholecystokinin in the central nervous system is unknown. The tetra peptide CCK-4 was previously observed to induce panic attacks in a majority of normal volunteers and patients with panic disorder. Furthermore, it had been dem
Publikováno v:
Journal of clinical psychopharmacology. 15(1)
Autor:
G.C. Dunbar, Ram K. Shrivastava, J. Mendels, J.P. Feighner, Louis F. Fabre, J. B. Cohn, R.R. Fieve
Publikováno v:
Journal of affective disorders. 28(2)
These data provide evidence for the antidepressant efficacy of paroxetine. Paroxetine- and imipramine-treated patients were significantly different from placebo-treated patients, but little different to each other, on all depressive outcome measures.